Veenstra T D, Fahnestock M, Kumar R
Nephrology Research Unit, Department of Medicine, Mayo Clinic/Foundation, Rochester, Minnesota 55905, USA.
Biochemistry. 1998 Apr 28;37(17):5988-94. doi: 10.1021/bi972965+.
1,25-Dihydroxyvitamin D3 (1,25(OH)2D3), the active metabolite of vitamin D, induces nerve growth factor (NGF) synthesis in a variety of different cell lines. The mechanism by which 1,25(OH)2D3 induces NGF, however, is poorly understood. We used a series of full-length and truncated NGF promoter-human growth hormone (hGH) reporter gene plasmids to investigate the mechanism of 1,25(OH)2D3-induced NGF expression in osteoblasts. Untransfected rat osteosarcoma cells (ROS 17/2.8) treated with 1,25(OH)2D3 showed a 2-fold increase in NGF expression compared to control cells. ROS 17/2.8 osteosarcoma cells were transfected with the NGF-hGH reporter plasmids and treated with 10(-)8 M 1,25(OH)2D3. The full-length NGF promoter (-1800 to +120)-hGH reporter construct showed an approximately 2-fold increase in hGH release. Plasmids with successive 5'-deletions showed enhanced hGH expression in treated cells and control cells. A similar series of NGF promoter-hGH reporter gene constructs, lacking the AP-1 site located within the first intron of the NGF gene, were also transiently transfected into ROS 17/2.8 cells. When these cells were treated with the same dose of 1,25(OH)2D3, no increase in hGH expression was seen compared to control cells, demonstrating that this AP-1 site is essential for 1,25(OH)2D3-mediated NGF up-regulation. Since 1,25(OH)2D3 is known to activate the transcription of several genes through its interaction with the vitamin D receptor (VDR), we performed a series of gel electrophoretic mobility shift assays to determine if the VDR binds directly to the AP-1 sequence. No evidence of VDR binding, either as a homodimer or as a heterodimer, to the AP-1 sequence was observed. Treatment of ROS 17/2.8 cells with 1,25(OH)2D3, however, resulted in an increase in AP-1 binding activity; however, no significant changes in c-jun and c-fos levels were observed. Our data show that in osteoblasts, 1,25(OH)2D3 induces NGF expression indirectly by increasing AP-1 binding activity.
1,25 - 二羟基维生素D3(1,25(OH)2D3)是维生素D的活性代谢产物,可在多种不同细胞系中诱导神经生长因子(NGF)的合成。然而,1,25(OH)2D3诱导NGF的机制尚不清楚。我们使用了一系列全长和截短的NGF启动子 - 人生长激素(hGH)报告基因质粒,来研究1,25(OH)2D3诱导成骨细胞中NGF表达的机制。与对照细胞相比,用1,25(OH)2D3处理的未转染大鼠骨肉瘤细胞(ROS 17/2.8)的NGF表达增加了2倍。将NGF - hGH报告质粒转染到ROS 17/2.8骨肉瘤细胞中,并用10^(-8) M 1,25(OH)2D3处理。全长NGF启动子(-1800至 +120)- hGH报告构建体显示hGH释放增加了约2倍。具有连续5'端缺失的质粒在处理细胞和对照细胞中均显示出增强的hGH表达。一系列类似的NGF启动子 - hGH报告基因构建体,缺失位于NGF基因第一内含子内的AP - 1位点,也被瞬时转染到ROS 17/2.8细胞中。当用相同剂量的1,25(OH)2D3处理这些细胞时,与对照细胞相比,未观察到hGH表达增加,这表明该AP - 1位点对于1,25(OH)2D3介导的NGF上调至关重要。由于已知1,25(OH)2D3通过与维生素D受体(VDR)相互作用来激活多个基因的转录,我们进行了一系列凝胶电泳迁移率变动分析,以确定VDR是否直接与AP - 1序列结合。未观察到VDR以同二聚体或异二聚体形式与AP - 1序列结合的证据。然而,用1,25(OH)2D3处理ROS 17/2.8细胞导致AP - 1结合活性增加;然而,未观察到c - jun和c - fos水平有显著变化。我们的数据表明,在成骨细胞中,1,25(OH)2D3通过增加AP - 1结合活性间接诱导NGF表达。